Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
- Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants - Initiation of Phase 3b study...









